BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study


4/12/2011 9:20:52 AM

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /PRNewswire/ -- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with thousands of patients successfully enrolled. A 30,000 patient enrollment study across 1500 sites is currently in-process with four more in the pipeline.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Current Ph IV success and activities are due to a specific business model Max Neeman created for such 'Observational studies' based on over 10 years of experience. Segments of the business model include: zonal stratification of >1000 sites and SOPs to improve quality of patient data retrieved in large studies. More than 30 CSRs have been developed to date.

The prevalence of diabetes in India is only second to China with 50.8 million people diagnosed with the disease and expected to rise steeply in the coming years. More large Ph IV studies are predicted and Max Neeman is prepared with a Ph IV strategy that is a combination of operational excellence (via Six Sigma practices), dedicated and trained project management teams, flexible delivery models, a customized approach and integrated technology. All these combine to deliver positive results on a customer's objective in a swift and cost effective manner.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to donald.swankie@neeman-medical.com or call +1.919.424.3345. www.neeman-medical.com

SOURCE Max Neeman International



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES